Cost of Revenue Comparison: AbbVie Inc. vs Pharming Group N.V.

Cost of Revenue: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. AbbVie Inc. and Pharming Group N.V. present a fascinating contrast in their cost of revenue from 2014 to 2023. AbbVie, a global biopharmaceutical leader, saw its cost of revenue grow by approximately 361%, from $4.4 billion in 2014 to $20.4 billion in 2023. This reflects its expansive growth and increased production capabilities. In contrast, Pharming Group N.V., a smaller biotech firm, experienced a more modest increase of around 505%, from $4.2 million to $25.2 million over the same period. This disparity highlights the scale and operational differences between large and small pharmaceutical companies. While AbbVie's costs surged, indicating robust expansion, Pharming's steady rise suggests a focused, niche market strategy. This comparison underscores the diverse paths companies take in navigating the competitive pharmaceutical landscape.